Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease

Seminars in Nephrology

Volumn 36, Issue 2, 2016, Pages 119-123

  Fishbane, Steven ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Anemia; Drug safety; Iron deficiency; Iron treatment

Indexed keywords

ANTIANEMIC AGENT; IRON; IRON DEXTRAN; IRON DERIVATIVE;

BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROPOIESIS; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; IRON OVERLOAD; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUPPLEMENTATION; ANAPHYLAXIS; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; METABOLISM; RISK ASSESSMENT;

ADMINISTRATION, INTRAVENOUS; ANAPHYLAXIS; ANEMIA, IRON-DEFICIENCY; HEMATINICS; HUMANS; IRON COMPOUNDS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT;

EID: 84969506829     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2016.02.006     Document Type: Review

References (38)

1. Van Wyck D.B. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin Nephrol 1989, 9(Suppl 2):21-24.
2. Fishbane S., Pollack S., Feldman H.I., Joffe M.M. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. J Am Soc Nephrol 2009, 4:57-61.
3. Stancu S., Stanciu A., Zugravu A., Bârsan L., Dumitru D., Lipan M., et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010, 55:639-647.
4. Markowitz G.S., Kahn G.A., Feingold R.E., Coco M., Lynn R.I. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997, 48:34-40.
5. Macdougall I.C., Tucker B., Thompson J., Tomson C.R., Baker L.R., Raine A.E. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996, 50:1694-1699.
6. Fudin R., Jaichenko J., Shostak A., Bennett M., Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998, 79:299-305.
7. Rotellar C., Borgiasz S., Winchester J.F., Rotellar E. Iron overload in patients on hemodialysis is directly related to the number of transfusions. Am J Kidney Dis 1988, 11:52.
8. Ali M., Fayemi A.O., Rigolosi R., Frascino J., Marsden T., Malcolm D. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 1980, 244:343-345.
9. Gokal R., Millard P.R., Weatherall D.J., Callender S.T., Ledingham J.G., Oliver D.O. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. QJM 1979, 48:369-391.
10. Van Wyck D.B., Stivelman J.C., Ruiz J., Kirlin L.F., Katz M.A., Ogden D.A. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989, 35:712-716.
11. The USRDS dialysis morbidity and mortality study (wave 1). Am J Kidney Dis 1996, 28(Suppl 2):S58-S78.
12. Fishbane S., Ungureanu V.D., Maesaka J.K., Kaupke C.J., Lim V., Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996, 28:529-534.
13. Susantitaphong P., Alqahtani F., Jaber B.L. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 2014, 39:130-141.
14. Sunder-Plassmann G., Hörl W.H. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995, 10:2070-2076.
15. DeVita M.V., Frumkin D., Mittal S., Kamran A., Fishbane S., Michelis M.F. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003, 60:335-340.
16. Fishbane S., Frei G.L., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995, 26:41-46.
17. Coyne D.W., Kapoian T., Suki W., Singh A.K., Moran J.E., Dahl N.V., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007, 18:975-984.
18. Kapoian T., O'Mara N.B., Singh A.K., Moran J., Rizkala A.R., Geronemus R., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008, 19:372-379.
19. Collins A.J., Ma J.Z., Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000, 20:345-349.
20. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
21. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
22. Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
23. Nishio A., Chhatkuli B.P., Ma J.Z., Kalantari K. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif 2013, 36:29-36.
24. Available from:. [cited 2015 October 2]. http://www.dopps.org/DPM/DPMSlideBrowser.aspx?type=Topic&id=1.
25. Feldman H.I., Santanna J., Guo W., Furst H., Franklin E., Joffe M., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002, 13:734-744.
26. Feldman H.I., Joffe M., Robinson B., Knauss J., Cizman B., Guo W., et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004, 15:1623-1632.
27. Miskulin D.C., Tangri N., Bandeen-Roche K., Zhou J., McDermott A., Meyer K.B., et al. Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014, 9:1930-1939.
28. Kshirsagar A.V., Freburger J.K., Ellis A.R., Wang L., Winkelmayer W.C., Brookhart M.A. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 2013, 8:e78930.
29. Michael B., Coyne D.W., Fishbane S., Folkert V., Lynn R., Nissenson A.R., et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002, 61:1830-1839.
30. Agarwal R., Kusek J.W., Pappas M.K. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015, 88:905-914.
31. Drakesmith H., Nemeth E., Ganz T. Ironing out ferroportin. Cell Metab 2015, 22:777-787.
32. US Department of Agriculture, Agricultural Research Service. What we eat in America, 2009-2010. 2012. [cited 2015 November 4]. Available from:. http://www.ars.usda.gov/SP2UserFiles/Place/80400530/pdf/1112/Table_1_NIN_GEN_11.pdf.
33. Parkkinen J., von Bonsdorff L., Peltonen S., Grönhagen-Riska C., Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000, 15:1827-1834.
34. Vaziri N.D. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013, 61:992-1000.
35. Rooyakers T., Stroes E., Kooistra M., et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002, 32(Suppl 1):9-16.
36. Charytan D.M., Pai A.B., Chan C.T., Coyne D.W., Hung A.M., Kovesdy C.P., et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015, 26:1238-1247.
37. Available from:. [cited 2015 October 15]. http://www.kdigo.org/clinical_practice:guidelines/pdf/KDIGO-Anemia%20GL.pdf.
38. EU Clinical Trials Register: Proactive IV Iron Therapy for Haemodialysis Patients (PIVOTAL), 2013. [cited 2015 September 9]. Available from:. http://https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB.